Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Full year trading statement

10 Jan 2025 07:00

RNS Number : 8294S
Anpario PLC
10 January 2025
 

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

 

Anpario plc("Anpario", the "Group" or the "Company")

 

Full year trading statement

 

Anpario plc (AIM:ANP), the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, provides the following trading update for the year ended 31 December 2024 ("FY 2024"). The figures set out in this announcement remain subject to audit.

 

Trading update

The Group, including three months of trading for Bio-Vet Inc., delivered a stronger than expected operating performance in the second half of 2024. Year-end sales were higher than anticipated, and the Group now expects revenue for the 12 months ended 31 December 2024 to be approximately £37.5m* (31 December 2023: £31.0m). This strong performance in revenue combined with the Group's high operational gearing and favourable year-end foreign exchange movements, will result in adjusted EBITDA being ahead of current market expectations*.

 

Bio-Vet Inc. had a strong final quarter due to heightened demand for its products, which support the health of dairy cows affected by avian influenza, and our Middle East and Africa segment delivered an outstanding sales performance.

 

Financial position

Our financial position remains strong, with year-end cash balances of £10.5m* (31 December 2023: £10.6m), after accounting for the acquisition of Bio-Vet Inc. and associated land and buildings for an initial cash consideration of US$6.3m, on a debt-free basis, which completed in September 2024.

 

Our strong balance sheet enables the Group to invest in innovative natural product solutions, expand our global reach and explore earnings enhancing and complementary acquisitions to continue the profitable development of the Group. We remain confident in our ability to capitalise on growth opportunities, delivering long-term benefits to all stakeholders.

 

FY2024 Results

The Group expects to publish its FY 2024 final results on or around 26 March 2025.

 

 

 

*Analyst consensus for FY 2024 immediately prior to this announcement was Revenue of £35.25m, EBITDA of £5.7m and net cash of £7.2m.

 

Enquiries

 

Anpario plc

Richard Edwards, Chief Executive Officer

+44(0)7776 417 129

Marc Wilson, Group Finance Director

+44(0)1909 537 380

Shore Capital

 

(Nominated Adviser and Broker)

+44 (0) 20 7408 4090

Stephane Auton

Corporate Advisory

David Coaten

Tom Knibbs

Henry Willcocks

Corporate Broking

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUUUGUPAPWB
Date   Source Headline
22nd Jun 202211:24 amRNSAGM Statement
16th Jun 20226:00 pmRNSResult of AGM
16th Jun 20227:00 amRNSAGM Statement
27th May 202212:56 pmRNSHolding(s) in Company
24th May 20221:10 pmRNSHolding(s) in Company
11th May 20227:00 amRNSNotice of AGM
10th May 20223:55 pmRNSHolding(s) in Company
5th May 20223:18 pmRNSHolding(s) in Company
4th May 20221:14 pmRNSTotal Voting Rights
28th Apr 202211:17 amRNSHolding(s) in Company
20th Apr 20221:49 pmRNSHolding(s) in Company
19th Apr 20223:47 pmRNSHolding(s) in Company
8th Apr 20227:00 amRNSDirectorate Change
6th Apr 202210:10 amRNSHolding(s) in Company
6th Apr 202210:09 amRNSTotal Voting Rights
1st Apr 20223:41 pmRNSHolding(s) in Company
25th Mar 202210:40 amRNSHolding(s) in Company
24th Mar 202212:57 pmRNSGrant of share awards
22nd Mar 20225:08 pmRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSFinal Results
8th Mar 20222:35 pmRNSBlock listing Interim Review
8th Mar 20222:34 pmRNSTotal Voting Rights
26th Jan 20227:00 amRNSFull Year Trading Statement
3rd Dec 20217:00 amRNSUK patent granted for Orego-stim
18th Nov 20211:17 pmRNSHolding(s) in Company
10th Nov 20217:00 amRNSNew Commitment to Sustainable Operations
3rd Nov 202112:04 pmRNSTotal Voting Rights
1st Nov 202110:03 amRNSHolding(s) in Company
26th Oct 20214:28 pmRNSHolding(s) in Company
12th Oct 20217:20 amRNSDirector/PDMR Shareholding
15th Sep 202111:51 amRNSHalf-year Report - Replacement
15th Sep 20217:00 amRNSHalf-year Report
3rd Aug 20219:52 amRNSTotal Voting Rights
20th Jul 20219:42 amRNSBlock listing Interim Review
9th Jul 20212:16 pmRNSAnpario receives “Community Business Hero Award"
17th Jun 20211:24 pmRNSResult of AGM
17th Jun 20217:00 amRNSAGM Statement
7th Jun 20213:58 pmRNSDirector/PDMR Shareholding
24th May 20219:48 amRNSHolding(s) in Company
18th May 20217:00 amRNSNotice of AGM
4th May 20214:16 pmRNSDirector/PDMR Shareholding
4th May 20214:10 pmRNSTotal Voting Rights
28th Apr 20214:00 pmRNSDirector/PDMR Shareholding
22nd Apr 20214:05 pmRNSDirector/PDMR Shareholding
19th Apr 20217:00 amRNSBoard update
13th Apr 20219:17 amRNSHolding(s) in Company
13th Apr 20219:17 amRNSHolding(s) in Company
6th Apr 20211:50 pmRNSDirector/PDMR Shareholding
30th Mar 20213:39 pmRNSDirector/PDMR Shareholding
17th Mar 20217:01 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.